Emd Serono Research & Development Institute, Inc.

This early study tested a new drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.

This study tested whether adding the drug Xevinapant (Debio 1143) to standard chemotherapy and radiation could help people with advanced head and neck cancer live longer without the cancer growing. The trial planned to enroll 730 adults with previously untreated, locally advanced…

This early-phase study tested a new drug (M9466) combined with chemotherapy in people with advanced solid tumors, including colorectal cancer. The main goal was to check safety and find the right dose. Only 3 people took part before the study was stopped early.

This study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people whose cancer was at high risk of relapse and who could not take the usual chemotherapy drug cisplatin.…

This early-phase study tested whether adding an experimental drug called xevinapant to standard weekly chemotherapy and radiation was safe and tolerable for people with advanced head and neck cancer. It involved 18 participants with cancer that could not be removed by surgery. Th…